5-bromo-1-(2-methoxyethyl)-1H-benzimidazole | 1374145-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-bromo-1-(2-methoxyethyl)-1H-benzimidazole
• 英文别名: 5-bromo-1-(2-methoxyethyl)benzimidazole
• CAS: 1374145-25-1
• 化学式: C₁₀H₁₁BrN₂O
• 分子量: 255.114
• InChiKey: FFUYWVOODFMGHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-1-(2-methoxyethyl)-1H-benzimidazole 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 methyl 2-chloro-5-[1-(2-methoxyethyl)-1H-benzoimidazol-5-yl]-4-nitrothiophene-3-carboxylate
  参考文献：
  名称：

  [EN] 3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS
  [FR] 3H-THIÉNO[3,4]PYRIMIDIN-4-ONE ET PYRROLOPYRIMID-4-ONE UTILISÉES COMME AGENTS ANTIBACTÉRIENS CONTRE LES BACTÉRIES À GRAM POSITIF

  摘要：

  公开号：

  WO2015128334A9
• 作为产物：
  描述：

  4-溴-1-氟-2-硝基苯 在 铁粉 、 氯化铵 、 对甲苯磺酸 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 水 、 甲苯 、 乙腈 为溶剂， 反应 22.0h， 生成 5-bromo-1-(2-methoxyethyl)-1H-benzimidazole
  参考文献：
  名称：

  [EN] 3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS
  [FR] 3H-THIÉNO[3,4]PYRIMIDIN-4-ONE ET PYRROLOPYRIMID-4-ONE UTILISÉES COMME AGENTS ANTIBACTÉRIENS CONTRE LES BACTÉRIES À GRAM POSITIF

  摘要：

  公开号：

  WO2015128334A9

文献信息

• Condensed derivatives of imidazole useful as pharmaceuticals
  申请人：LABORATOIRE BIODIM

  公开号：EP2913330A1

  公开（公告）日：2015-09-02

  The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

  该发明涉及化合物（I）及其酸盐和碱盐： 其中： 虚线表示双键； X为N或C-R1，Y为N或C-R2，X和Y不同时为N； A选自苯基、萘基和（5-11）成员单环或双环不饱和环或杂环，可能按申请中定义进行取代， A还可以包括另一个（4-7）成员杂环，该杂环为单环、融合、饱和或不饱和，多环系统则包括最多14个成员和最多5个N、O和S中选择的杂原子； B为氢或按申请中定义的取代基，或 B为含有1-3个N、O和S中选择的杂原子的（4-10）成员单环或双环饱和或不饱和杂环，并可能按申请中定义进行取代； 当X为N且Y为C-R2时，B不是氢； R1为氢或按申请中定义的取代基； B和R1不能同时为氢； R2为氢或卤素； 它们的制备，它们在抗菌预防和治疗中的用途，单独或与抗菌药物、抗毒力剂或增强宿主先天免疫力的药物联合使用，以及含有它们的药物组合物和联合物。
• Pyridine Derivative and Medicinal Agent
  申请人：Fujihara Hidetaka

  公开号：US20130225548A1

  公开（公告）日：2013-08-29

  A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, which may be substituted by an optionally substituted alkyl group, a hydroxy group, a halogen atom or a group represented by general formula [2]. In formula [2], -L 1 -L 2 -L 3 -R A [2] L 1 and L 3 independently represent a single bond, an alkylene group or a cycloalkylene group; L 2 represents a single bond, O, or NR B ; R B represents H or an optionally substituted alkyl group; and R A represents B, an amino group, a cyano group, a hydroxy group, an alkoxy group, an aryl group, a monoalkylamino group, a dialkylamino group, a carbamoyl group, an alkyloxycarbonyl group, a monoalkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkylcarbonylamino group, and a saturated heterocyclic group, among other groups.

  本发明的一个主要对象是提供一种由下述通用式[1]表示的新型吡啶衍生物或其药学上可接受的盐。在式[1]中，R代表芳基或杂芳基，可以被可选择地取代的烷基、羟基、卤原子或通式[2]所代表的基团所取代。在式[2]中，-L1-L2-L3-RA[2]L1和L3独立地代表单键、烷基或环烷基；L2代表单键、O或NRB；RB代表氢或可选择地取代的烷基；RA代表B、氨基、氰基、羟基、烷氧基、芳基、单烷基氨基、双烷基氨基、氨基甲酰基、烷氧羰基、单烷基氨基羰基、双烷基氨基羰基、烷基羰基氨基和饱和杂环基等基团，以及其他基团。
• PYRIDINE DERIVATIVE AND MEDICINAL AGENT
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP2634176A1

  公开（公告）日：2013-09-04

  [Problem to be Solved by the Invention] A main object of the present invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. [Means of Solving the Problems] A pyridine derivative or a pharmaceutically acceptable salt represented by the following genaral formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, wherein each of the aryl group and the heteroaryl group may be substituted by one or two substituents independently selected from the group consisting of an optionally substituted alkyl group, a hydroxy group, a halogen atom and a group represented by general formula [2]. In formula [2],         -L1-L2-L3-RA L1 and L3 independently represent a single bond, an alkylene group or a cycloalkylene group; L2 represents a single bond, O, or NRB; RB represents H or an optionally substituted alkyl group; RA represents H, an amino group, a cyano group, a hydroxy group, an alkoxy group, an aryl group, a monoalkylamino group, a dialkylamino group, a carbamoyl group, an alkyloxycarbonyl group, a monoalkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkylcarbonylamino group, a saturated heterocyclic group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group or an optionally substituted heteroaryl group.

  [本发明要解决的问题］ 本发明的主要目的是提供一种新型吡啶衍生物或其药学上可接受的盐。 [解决问题的方法］ 由下式[1]代表的吡啶衍生物或其药学上可接受的盐。 在式[1]中，R 代表芳基或杂芳基，其中每个芳基和杂芳基可被一个或两个取代基取代，这些取代基独立地选自任选取代的烷基、羟基、卤素原子和通式[2]所代表的基团组成的组。在式 [2] 中 -L1-L2-L3-RA L1 和 L3 各自代表单键、亚烷基或环烷基；L2 代表单键、O 或 NRB；RB 代表 H 或任选取代的烷基；RA 代表 H、氨基、氰基、羟基、烷氧基、芳基、单烷基氨基、二烷基氨基、氨基甲酰基、烷氧基羰基、单烷基氨基羰基、二烷基氨基羰基、烷基羰基氨基、饱和杂环基、任选取代的烷基、任选取代的环烷基或任选取代的杂芳基。
• 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents
  申请人：LABORATOIRE BIODIM

  公开号：EP2913333A1

  公开（公告）日：2015-09-02

  The invention relates to novel heteroaromatic derivatives of formula (I) and their addition salts thereof with acids and bases; their preparation, their use as drugs and pharmaceutical compositions and associations containing them. wherein A, B, T, V, X and Y represent organic substituents as defined herein, The compounds of formula (I) are able to inhibit the activity of the Gram-positive bacterial DltA enzyme and they are used to prevent and/or treat Gram-positive bacterial infections in humans or animals, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity,

  本发明涉及式（I）的新型杂芳香族衍生物及其与酸和碱的加成盐；它们的制备、作为药物和药物组合物的用途以及含有它们的组合物。 其中 A、B、T、V、X 和 Y 代表本文定义的有机取代基、 式（I）化合物能够抑制革兰氏阳性菌 DltA 酶的活性，它们可单独或与抗菌剂、抗病毒剂或增强宿主先天免疫力的药物一起用于预防和/或治疗人或动物的革兰氏阳性菌感染、
• Heteroaromatic derivatives and their use as pharmaceuticals
  申请人：MUTABILIS

  公开号：US10301305B2

  公开（公告）日：2019-05-28

  The invention relates to the compounds (I) and their acids and bases salts: wherein: Formula (I) the dotted line indicates a double bond; X is N or C—R1 and Y is N or C—R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is selected from the group of substituents as defined in the application, or B is a 4 or (6-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, linked by a carbon atom, and possibly substituted as defined in the application; R1 is Hydrogen or a substituent as defined in the application; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

  本发明涉及化合物（I）及其酸盐和碱盐： 其中：式（Ⅰ）中虚线表示双键；X 为 N 或 C-R1，Y 为 N 或 C-R2，X 和 Y 不能同时为 N；A 选自苯基、萘基和(5-11)个成员的单环或双环不饱和环或杂环组成的组，这些环或杂环可能如本申请中所定义的那样被取代，A 还可以包括另一个(4-7)个成员的杂环，所述杂环是单环、融合的、饱和的或不饱和的，多环体系最多包括 14 个成员和最多 5 个选自 N、O 和 S 的杂原子；B 选自本申请中所定义的取代基组，或者 B 是 4 或（6-10）个成员的单环或双环饱和或不饱和杂环，含有 1-3 个选自 N、O 和 S 的杂原子，由一个碳原子连接，并可能被本申请中所定义的取代；R1 是氢或本申请中所定义的取代基；R2 是氢或卤素；它们的制备方法，它们在抗菌预防和治疗中的用途（单独使用或与抗菌剂、抗病毒剂或增强宿主先天免疫力的药物联合使用），以及含有它们的药物组合物和组合物。